Get started
Author

Anna Santarsieri

Observed names: A. Santarsieri, Anna Santarsieri (16676331), Santarsieri A, Santarsieri, Anna
Observed institutions: Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Wellcome Sanger Institute, Addenbrooke's Hospital, Anglia Ruskin University
ORCID: 0000-0002-4449-2196
Observed ORCID: 0000-0002-4449-2196
OpenAlex ID: A5021039318
The long-term effects of chemotherapy on normal blood cells
2025 · Emily Mitchell, My H. Pham, et al. · Nature Genetics · 45
PDF
Incidence and outcomes of post‐transplant lymphoproliferative disease after 5365 solid‐organ transplants over a 20‐year period at two UK transplant centres
2022 · Anna Santarsieri, John F. Rudge, et al. · British Journal of Haematology · 24
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study
2023 · Ann Tivey, Rohan Shotton, et al. · Blood Advances · 21
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study
2024 · Anna Santarsieri, Emily Mitchell, et al. · The Lancet Oncology · 12
PDF
Minimising the Toxicities of First Line Hodgkin Lymphoma Treatment in the Modern Era
2022 · Annabel M. Follows, Anna Santarsieri · Cancers · 12
PDF
Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
2022 · Anna Santarsieri, Emily Mitchell, et al. · Blood · 10
Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp
2021 · Anna Santarsieri, Katherine Sturgess, et al. · Blood · 8
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
2026 · Juan Pablo Alderuccio, Diva Baggio, et al. · Blood · 7
Glofitamab and Epcoritamab in the Real World: A UK Multicentre Retrospective Analysis of Efficacy, Tolerability and Practical Implications
2024 · Euan Haynes, Kushani Ediriwickrema, et al. · Blood · 7
PDF
R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
2022 · Anna Santarsieri, Rory Bennett, et al. · Blood · 6
Managing relapsed refractory lymphoma with palliative oral chemotherapy: A multicentre retrospective study
2022 · Simon J. Bulley, Anna Santarsieri, et al. · eJHaem · 6
An international survey of clinicians regarding their management of venous thromboembolism following the initial 3–6 months of anticoagulation
2020 · E. Banham-Hall, A. Allison, et al. · Journal of Thrombosis and Thrombolysis · 6
Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious
2019 · Anna Santarsieri, Katherine Sturgess, et al. · Blood · 5
The long-term effects of chemotherapy on normal blood cells
2024 · Emily Mitchell, My H. Pham, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
Relapsed mantle cell lymphoma presenting with lactic acidosis and hypoglycemia: A case report
2023 · Lucy Carson, Andrew Johnston, et al. · Clinical Case Reports · 3
PDF
The Burkitt Lymphoma International Prognostic Index (BL-IPI)
2020 · Adam J Olszewski, Lasse H. Jakobsen, et al. · Blood · 2
Relapsed/Refractory Hodgkin lymphoma after first-line escalated beacopdac: Adverse outcomes are overcome by use of second-line targeted therapy - an international real-world analysis
2025 · Lisa Jeffers, Anna Santarsieri, et al. · Blood · 1
339 | Outcomes in an International Multicentre Study of 600 Patients With Cns Relapse of Large B Cell Lymphoma: Compartment of Relapse Is Prognostic
2025 · D. Baggio, S. Han, et al. · Hematological Oncology · 1
PDF
326 | Glofitamab and Epcoritamab for Large B Cell Lymphoma in 319 Real World Patients: a Retrospective Uk Analysis of Efficacy, Tolerability and Practical Implications
2025 · E. Haynes, W. Townsend, et al. · Hematological Oncology · 1
PDF
Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort
2024 · Juan Pablo Alderuccio, Jahanzaib Khwaja, et al. · Blood · 1
Replacing procarbazine with dacarbazine in escalated BEACOPP reduces clinical toxicity with no loss of efficacy yet protects stem cells from excess somatic mutational damage
2023 · A. Santarsieri, E. Mitchell, et al. · Hematological Oncology · 1
PDF
P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
2022 · Anna Santarsieri, Katherine Sturgess, et al. · HemaSphere · 1
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
2022 · Wilson, Matthew R., Eyre, Toby A., et al. · Repository@Nottingham (University of Nottingham) · 1
PDF
A rare case of bone marrow infiltration by medulloblastoma in a child
2019 · Anna Santarsieri, Emmy Dickens, et al. · British Journal of Haematology · 1
PDF
Interrupted aorta in mosaic Turner syndrome
2011 · Vikrant Nayar, Anna Santarsieri, et al. · Cardiology Journal · 1
Works count: 42
Citation count: 187
H-index: 7
I10-index: 6
Year
Topic
Type